Skip to main content
. 2023 Apr 15;49(3):334–340. doi: 10.1590/S1677-5538.IBJU.2023.0054

Table 1. Complication rate between TPPB and TRPB and between TPPB groups 1 and 2.

Complication Transperineal (N=283) Transrectal (N=513) p value
All – no. (%) 156 (55.1) 420 (81.9) <0.001
Hematuria – no. (%) 138 (48.8) 340 (66.3) <0.001
Rectal bleeding – no. (%) 10 (3.5) 93 (18.1) <0.001
Pain without need of analgesia – no. (%) 12 (4.2) 48 (9.4) 0.009
Pain requiring analgesia – no. (%) 12 (4.2) 23 (4.5) 0.87
Urinary retention – no. (%) 3 (1.1) 12 (2.3) 0.20
Prostatitis – no. (%) 0 3 (0.6) 0.56
Other – no. (%) 7 (2.5) 15 (2.9) 0.71
Complication TPPB Group 1 (N=142) TPPB Group 2 (N=141) p value
All – no. (%) 95 (66.9) 61 (43.3) <0.001
Hematuria – no. (%) 84 (59.2) 54 (38.3) <0.001
Rectal bleeding – no. (%) 9 (6.3) 1 (0.7) 0.02
Pain without need of analgesia – no. (%) 8 (5.6) 4 (2.8) 0.24
Pain requiring analgesia – no. (%) 8 (5.6) 4 (2.8) 0.24
Urinary retention – no. (%) 2 (1.4) 1 (0.7) >0.99
Prostatitis – no. (%) 0 0 -
Other – no. (%) 3 (2.1) 4 (2.8) 0.712

TPPB = transperineal prostate biopsy; TRPB = transrectal prostate biopsy; no = number; % = percentage Group 1: TPPB y in the first 6 months (March to August 2021); Group 2: TPPB in the following 6 months (September 2021 to February 2022)